85 related articles for article (PubMed ID: 38667336)
1. Peripheral lymphocyte subsets as predicting factors for molecular recurrence after imatinib discontinuation in a phase 2 imatinib discontinuation trial in patients with chronic myeloid leukemia.
Braga AGO; Barbosa Pagnano KB; Campioni MDP; Lopes ABP; Duarte GO; Metze K; Lorand-Metze I
Hematol Transfus Cell Ther; 2024; 46(3):268-272. PubMed ID: 37442648
[TBL] [Abstract][Full Text] [Related]
2. Prediction of deep molecular response in chronic myeloid leukemia using supervised machine learning models.
Zad Z; Bonecker S; Wang T; Zalcberg I; Stelzer GT; Sabioni B; Gutiyama LM; Fleck JL; Paschalidis IC
Leuk Res; 2024 Jun; 141():107502. PubMed ID: 38636414
[No Abstract] [Full Text] [Related]
3. Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety.
Laganà A; Scalzulli E; Bisegna ML; Carmosino I; Ielo C; Costa A; Torrieri L; Totaro M; Martelli M; Breccia M
Expert Opin Drug Saf; 2024 Jun; ():. PubMed ID: 38873693
[TBL] [Abstract][Full Text] [Related]
4. Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib.
Pagnano KBB; Miranda EC; Delamain MT; Duarte GO; de Paula EV; Lorand-Metze I; de Souza CA
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):728-733. PubMed ID: 28822797
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice.
Breccia M; Efficace F; Colafigli G; Scalzulli E; Di Prima A; Martelli M; Foà R
Expert Rev Hematol; 2020 Dec; 13(12):1311-1318. PubMed ID: 33205694
[No Abstract] [Full Text] [Related]
6. High Level of CD8
Kwaśnik P; Zaleska J; Link-Lenczowska D; Zawada M; Wysogląd H; Ochrem B; Bober G; Wasilewska E; Hus I; Szarejko M; Prejzner W; Grzybowska-Izydorczyk O; Klonowska-Szymczyk A; Mędraś E; Kiełbus M; Sacha T; Giannopoulos K
Cells; 2024 Apr; 13(8):. PubMed ID: 38667336
[TBL] [Abstract][Full Text] [Related]
7. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
[TBL] [Abstract][Full Text] [Related]
8. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.
Takahashi N; Tauchi T; Kitamura K; Miyamura K; Saburi Y; Hatta Y; Miyata Y; Kobayashi S; Usuki K; Matsumura I; Minami Y; Usui N; Fukuda T; Takada S; Ishikawa M; Fujimaki K; Gomyo H; Sasaki O; Ohishi K; Miyake T; Imai K; Suzushima H; Mitsui H; Togitani K; Kiguchi T; Atsuta Y; Ohtake S; Ohnishi K; Kobayashi Y; Kiyoi H; Miyazaki Y; Naoe T;
Int J Hematol; 2018 Feb; 107(2):185-193. PubMed ID: 28929332
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells.
Ross DM; Pagani IS; Shanmuganathan N; Kok CH; Seymour JF; Mills AK; Filshie RJ; Arthur CK; Dang P; Saunders VA; Braley J; Yong AS; Yeung DT; White DL; Grigg AP; Schwarer AP; Branford S; Hughes TP;
Leukemia; 2018 Dec; 32(12):2572-2579. PubMed ID: 30315232
[TBL] [Abstract][Full Text] [Related]
10. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.
Hughes A; Clarson J; Tang C; Vidovic L; White DL; Hughes TP; Yong AS
Blood; 2017 Mar; 129(9):1166-1176. PubMed ID: 28049640
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of Kashmir.
Azad NA; Shah ZA; Pandith AA; Khan MS; Rasool R; Rasool J; Aziz SA
Asian Pac J Cancer Prev; 2018 Jun; 19(6):1479-1485. PubMed ID: 29936718
[TBL] [Abstract][Full Text] [Related]
12. Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy.
Salmon M; White HE; Zizkova H; Gottschalk A; Motlova E; Cerveira N; Colomer D; Coriu D; Franke GN; Gottardi E; Izzo B; Jurcek T; Lion T; Schäfer V; Venturi C; Vigneri P; Zawada M; Zuna J; Hovorkova L; Koblihova J; Klamova H; Markova MS; Srbova D; Benesova A; Polivkova V; Zackova D; Mayer J; Roeder I; Glauche I; Ernst T; Hochhaus A; Polakova KM; Cross NCP
Leukemia; 2022 Jul; 36(7):1879-1886. PubMed ID: 35676453
[TBL] [Abstract][Full Text] [Related]
13. Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia.
Flynn KE; Atallah E; Lin L; Shah NP; Silver RT; Larson RA; Panilla-Ibarz J; Thompson JE; Oehler VG; Radich JP; Kota V; Mauro MJ; Schiffer CA; Cortes J; Weinfurt KP
Haematologica; 2022 Nov; 107(11):2641-2649. PubMed ID: 35511672
[TBL] [Abstract][Full Text] [Related]
14. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors.
Haddad FG; Sasaki K; Issa GC; Garcia-Manero G; Ravandi F; Kadia T; Cortes J; Konopleva M; Pemmaraju N; Alvarado Y; Yilmaz M; Borthakur G; DiNardo C; Jain N; Daver N; Short NJ; Jabbour E; Kantarjian H
Am J Hematol; 2022 Jul; 97(7):856-864. PubMed ID: 35357036
[TBL] [Abstract][Full Text] [Related]
15. Assessment of quantitative polymerase chain reaction for BCR-ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?
Dominy KM; Claudiani S; O'Hare M; Szydlo R; Gerrard G; Foskett P; Foroni L; Milojkovic D; Apperley JF; Khorashad J
Br J Haematol; 2022 Apr; 197(1):52-62. PubMed ID: 34997766
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]